BioSyent to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
April 14 2021 - 7:00AM
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce
that it will be presenting at the upcoming Bloom Burton & Co.
Healthcare Investor Conference. The conference will be held
virtually on Tuesday, April 20 and Wednesday, April 21, 2021
between 8:30 am and 5:00 pm ET. Mr. René Goehrum,
President and CEO of BioSyent, will present to investors an
overview of BioSyent’s business and corporate activities on April
21 at 11:00 am. Mr. Goehrum will also be available to meet
virtually with investors on a one-on-one basis during the
conference. These one-on-one meetings can be requested by attendees
after registering for the conference:
https://www.meetmax.com/sched/event_71993/conference_register.html.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty, and international business units.
As of the date of this press release, the
Company has 12,706,275 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to
risks and uncertainties that may cause actual results or outcomes
to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development,
future revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024